Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Relapsed or refractory multiple myeloma, drawn from the whole corpus: 88 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Sequencing CAR-T and bispecifics, and whether a second T-cell therapy works after the first.
Infections on continuous BCMA bispecifics, and whether fixed-duration dosing is safe.
CAR-T manufacturing capacity, slots and cost, and the patients who progress while waiting.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 26 changes by month →When this page itself was last checked or edited.
ORR 97%.
36-month PFS 83.
A milestone in how this cancer is treated.
Relapsed myeloma after ≥1 prior line, lenalidomide-refractory (CARTITUDE-4)
Relapsed myeloma after ≥1 line, lenalidomide-refractory